US5833975A
(en)
*
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
US4769330A
(en)
*
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
US5505941A
(en)
*
|
1981-12-24 |
1996-04-09 |
Health Research, Inc. |
Recombinant avipox virus and method to induce an immune response
|
US4722848A
(en)
*
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
US4603112A
(en)
*
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
US5110587A
(en)
*
|
1981-12-24 |
1992-05-05 |
Health Research, Incorporated |
Immunogenic composition comprising synthetically modified vaccinia virus
|
US5155020A
(en)
*
|
1989-03-08 |
1992-10-13 |
Health Research Inc. |
Recombinant poxvirus host range selection system
|
US5364773A
(en)
*
|
1991-03-07 |
1994-11-15 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
US5174993A
(en)
*
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
US5378457A
(en)
*
|
1981-12-24 |
1995-01-03 |
Virogenetics Corporation |
Interferon sensitive recombinant poxvirus vaccine
|
US4882278A
(en)
*
|
1983-04-29 |
1989-11-21 |
President And Fellows Of Harvard College |
Non-toxinogenic vibrio cholerae mutants
|
US4923808A
(en)
*
|
1985-03-12 |
1990-05-08 |
Genentech, Inc. |
Method for identifying mutants secreting high levels of heterologous proteins
|
US5141742A
(en)
*
|
1986-02-07 |
1992-08-25 |
Oncogen |
Vaccines against melanoma
|
US5122599A
(en)
*
|
1986-08-13 |
1992-06-16 |
Molecular Diagnostics, Inc. |
CDNAS coding for members of the carcinoembryonic antigen family
|
US6013772A
(en)
*
|
1986-08-13 |
2000-01-11 |
Bayer Corporation |
Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
|
US5274087A
(en)
*
|
1986-08-13 |
1993-12-28 |
Molecular Diagnostics, Inc. |
cDNA coding for carcinoembryonic antigen (CEA)
|
US5504005A
(en)
*
|
1987-03-02 |
1996-04-02 |
Albert Einstein College Of Medicine Of Yeshiva University |
Recombinant mycobacterial vaccine
|
US5284931A
(en)
*
|
1987-05-04 |
1994-02-08 |
Dana Farber Cancer Institute |
Intercellular adhesion molecules, and their binding ligands
|
US4956281A
(en)
*
|
1987-06-03 |
1990-09-11 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
|
US6699475B1
(en)
*
|
1987-09-02 |
2004-03-02 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
DE68922757T2
(de)
*
|
1988-01-29 |
1995-11-16 |
Lilly Co Eli |
Vektoren, Zusammensetzungen und Verfahren zur Expression von einem menschlichen Adevoharzimomantigen.
|
US5093258A
(en)
*
|
1988-08-26 |
1992-03-03 |
Therion Biologics Corporation |
Recombinant fowlpox virus and recombination vector
|
US5225336A
(en)
*
|
1989-03-08 |
1993-07-06 |
Health Research Incorporated |
Recombinant poxvirus host range selection system
|
CH682669A5
(fr)
*
|
1989-03-08 |
1993-10-29 |
Health Research Inc |
Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants.
|
US5703055A
(en)
*
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
EP0463157A4
(en)
|
1990-01-24 |
1992-06-03 |
Biogen, Inc. |
Lfa-3 as a vaccine adjuvant
|
US5204243A
(en)
*
|
1990-02-14 |
1993-04-20 |
Health Research Incorporated |
Recombinant poxvirus internal cores
|
US5279833A
(en)
*
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
US6071716A
(en)
*
|
1990-10-01 |
2000-06-06 |
Dana-Farber Cancer Institute |
DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
|
SE9003978D0
(sv)
*
|
1990-12-13 |
1990-12-13 |
Henrik Garoff |
Dna expressionssystem baserade paa ett virus replikon
|
KR100242671B1
(ko)
*
|
1991-03-07 |
2000-03-02 |
고돈 에릭 |
유전학적으로 처리한 백신 균주
|
PT503648E
(pt)
*
|
1991-03-12 |
2000-10-31 |
Biogen Inc |
Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2
|
ES2206446T3
(es)
*
|
1991-05-06 |
2004-05-16 |
The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services |
Virus recombinante que expresa un antigeno carcinoembrionico y metodos de uso del mismo.
|
US5541104A
(en)
*
|
1991-05-23 |
1996-07-30 |
Ludwig Institute For Cancer Research |
Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
|
US5342774A
(en)
*
|
1991-05-23 |
1994-08-30 |
Ludwig Institute For Cancer Research |
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
|
US6235525B1
(en)
*
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
US5283185A
(en)
*
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
CA2139655C
(en)
*
|
1992-07-06 |
2008-05-13 |
John J. Mekalanos |
Deletion mutants as vaccines for cholera
|
ATE280180T1
(de)
*
|
1992-08-31 |
2004-11-15 |
Ludwig Inst Cancer Res |
Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
|
US5405940A
(en)
*
|
1992-08-31 |
1995-04-11 |
Ludwig Institute For Cancer Research |
Isolated nonapeptides derived from MAGE genes and uses thereof
|
US5462871A
(en)
*
|
1992-08-31 |
1995-10-31 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules which encode MAGE derived nonapeptides
|
WO1994019482A1
(en)
*
|
1993-02-22 |
1994-09-01 |
The General Hospital Corporation |
Heterologous antigens in live cell vaccine strains
|
KR960701988A
(ko)
*
|
1993-04-20 |
1996-03-28 |
윌리엄 에스. 로빈슨 |
세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
|
US5919676A
(en)
*
|
1993-06-24 |
1999-07-06 |
Advec, Inc. |
Adenoviral vector system comprising Cre-loxP recombination
|
US5858776A
(en)
*
|
1993-11-03 |
1999-01-12 |
Repligen Corporation |
Tumor cells with increased immunogenicity and uses therefor
|
US6015686A
(en)
*
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
TW442569B
(en)
*
|
1993-10-25 |
2001-06-23 |
Canji Inc |
Recombinant adenoviral vector
|
US5554506A
(en)
*
|
1994-03-24 |
1996-09-10 |
Ludwig Institute For Cancer Research |
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
|
US5554724A
(en)
*
|
1994-03-24 |
1996-09-10 |
University Of Leiden |
Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
|
US5851523A
(en)
*
|
1994-03-24 |
1998-12-22 |
Ludwig Institute For Cancer Research. |
Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
|
US5585461A
(en)
*
|
1994-03-24 |
1996-12-17 |
Ludwig Institute For Cancer Research |
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
|
US5686068A
(en)
*
|
1994-03-24 |
1997-11-11 |
Ludwig Institute For Cancer Research |
Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
|
US5651981A
(en)
*
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
SE9401091D0
(sv)
*
|
1994-03-31 |
1994-03-31 |
Bioption Ab |
Alphavirus cDNA vectors
|
SE9401709D0
(sv)
*
|
1994-05-18 |
1994-05-18 |
Mathilda Sjoeberg |
Improved alphavirus vectors for expression of heterologous DNA
|
US5527928A
(en)
*
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
WO1996011279A2
(en)
|
1994-10-03 |
1996-04-18 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
|
AU688606B2
(en)
*
|
1994-10-03 |
1998-03-12 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
US6045802A
(en)
*
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
US6001349A
(en)
*
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
US5707618A
(en)
*
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
US5792462A
(en)
*
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US6013516A
(en)
*
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
WO1997015597A1
(en)
|
1995-10-25 |
1997-05-01 |
Centocor B.V. |
HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
|
EP0866721A4
(de)
*
|
1995-12-08 |
2003-06-04 |
Univ Alabama Birmingham Res Fo |
Adenovirale zielvektoren
|
FR2746110B1
(fr)
*
|
1996-03-14 |
1998-04-17 |
|
Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
|
AU731860B2
(en)
*
|
1996-07-25 |
2001-04-05 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Recombinant pox virus for immunization against tumor-associated antigens
|
AU718945B2
(en)
|
1996-07-25 |
2000-05-04 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
GB9621680D0
(en)
*
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
US5994132A
(en)
*
|
1996-10-23 |
1999-11-30 |
University Of Michigan |
Adenovirus vectors
|
WO1998029556A1
(en)
|
1996-12-31 |
1998-07-09 |
The Wistar Institute |
Recombinant adenoviral vector expressing antigens associated with colorectal tumors
|
US5990091A
(en)
*
|
1997-03-12 |
1999-11-23 |
Virogenetics Corporation |
Vectors having enhanced expression, and methods of making and uses thereof
|
AU741747B2
(en)
*
|
1997-05-13 |
2001-12-06 |
University Of North Carolina At Chapel Hill, The |
Lentivirus-based gene transfer vectors
|
US5965535A
(en)
*
|
1997-09-12 |
1999-10-12 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
WO1999015641A1
(en)
*
|
1997-09-24 |
1999-04-01 |
The Regents Of The University Of California |
Non-primate lentiviral vectors and packaging systems
|
US7084239B1
(en)
*
|
1997-10-08 |
2006-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cancer peptides of NY-ESO-1/CAG-3
|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
US20070048860A1
(en)
*
|
1997-10-10 |
2007-03-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Carcinoembryonic antigen (CEA) peptides
|
US5994136A
(en)
*
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
CA2792479A1
(en)
|
1998-02-27 |
1999-09-02 |
The Trustees Of The University Of Pennsylvania |
Vaccines, immunotherapeutics and methods for using the same
|
CA2322624A1
(en)
|
1998-03-20 |
1999-09-23 |
Genzyme Corporation |
Induction of immunity against tumor self-antigens
|
US6171855B1
(en)
*
|
1998-05-28 |
2001-01-09 |
The Regents Of The University Of Michigan |
Vectors
|
US6407063B1
(en)
*
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
DE69936061T2
(de)
*
|
1998-12-09 |
2008-01-17 |
Therion Biologics Corp., Cambridge |
Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden
|
AU1013601A
(en)
*
|
1999-10-22 |
2001-05-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
EP1246646A2
(de)
*
|
2000-01-05 |
2002-10-09 |
Aventis Pasteur Limited |
Verstärkung der immunreaktion gegen ein antigen durch eine vorsensibilisierung mit einem induzierenden agens vor der immunisierung mit dem induzierenden agens und dem antigen
|
EP1561817A3
(de)
*
|
2000-07-31 |
2005-09-14 |
Aventis Pasteur Limited |
Modifiziertes CEA und entsprechende verwendungen
|
US20040091995A1
(en)
*
|
2001-06-15 |
2004-05-13 |
Jeffrey Schlom |
Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
|
US20030113919A1
(en)
*
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
AU2003228339A1
(en)
|
2002-03-20 |
2003-10-08 |
Aventis Pasteur, Inc. |
Prevention and treatment of disease using angiogenesis-and/or tumor antigens
|
US7786278B2
(en)
*
|
2002-04-09 |
2010-08-31 |
Sanofi Pasteur Limited |
Modified CEA nucleic acid and expression vectors
|